WASHINGTON — President Trump announced a significant drug pricing agreement with Regeneron on Thursday, marking the conclusion of the 17 deals initially pursued by the White House the previous year.
Under the terms of this private agreement, Regeneron will lower drug prices for Medicaid, provide the cholesterol medication Praluent through TrumpRx for $225, and allocate $27 billion towards drug development within the United States.
Additionally, Regeneron disclosed on the same day that the Food and Drug Administration had approved Otarmeni, the first gene therapy approved under the agency’s new National Priority Voucher program. Early trials indicated that the drug offered modest improvements in hearing for individuals with a rare form of hearing loss. However, its development has faced opposition from segments of the Deaf community. Regeneron intends to make the drug available free of charge to American patients.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
.
